Closing a gap in the literature, this is the only series to cover this important topic in organic and biochemistry. Drawing upon the combined expertise of the international „who’s who“ in amino acid research, these volumes represent a real benchmark for amino acid chemistry, providing a comprehensive discussion of the occurrence, uses and applications of amino acids and, by extension, their polymeric forms, peptides and proteins. The practical value of each volume is heightened by the inclusion of experimental procedures.

Volume 1: Origins and Synthesis of Amino Acids
Volume 2: Modified Amino Acids, Organocatalysis and Enzymes
Volume 3: Building Blocks, Catalysis and Coupling Chemistry
Volume 4: Protection Reactions, Medicinal Chemistry, Combinatorial Synthesis
Volume 5: Analysis and Function of Amino Acids and Peptides
Volume 6: Peptide Natural Products and Amino Acid Chemistry Development

The fourth volume in this six-volume series is structured in three main sections. The first section is about protection reactions and amino acid-based peptidomimetics. The second, and most extensive, part is devoted to the medicinal chemistry of amino acids. It includes, among others, the chemistry of alpha- and beta amino acids, peptide drugs, and advances in N- and O-glycopeptide synthesis. The final part deals with amino acids in combinatorial synthesis. Methods, such as phage display, library peptide synthesis, and computational design are described.

Andrew Hughes is a reader and Head of the Department of Chemistry at La Trobe University, Melbourne, Australia. He obtained his degrees from the University of Western Australia, before taking up post-doctoral appointments at the University of Cambridge starting in 1989. After three years working with Professor Andrew Holmes, he joined Professor Steven Ley's group. While at Cambridge he was appointed the Shell Research Fellow at Robinson College. His interests lie in the general field of asymmetric synthesis and methodology, with a recent focus on amino acid chemistry.
Edited by
Andrew B. Hughes

Amino Acids, Peptides
and Proteins in
Organic Chemistry
### Further Reading

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>ISBN</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="#">Ideas in Chemistry and Molecular Sciences</a></td>
<td>Pignataro, B. (ed.)</td>
<td>978-3-527-32539-9</td>
</tr>
<tr>
<td><a href="#">Advances in Synthetic Chemistry</a></td>
<td>Theophil Eicher, Siegfried Hauptmann and Andreas Speicher</td>
<td></td>
</tr>
<tr>
<td><a href="#">The Chemistry of Heterocycles</a></td>
<td>Royer, J. (ed.)</td>
<td>978-3-527-32036-3</td>
</tr>
<tr>
<td><a href="#">Structure, Reactions, Synthesis, and Applications</a></td>
<td>Reek, J. N. H., Otto, S.</td>
<td></td>
</tr>
<tr>
<td><a href="#">Dynamic Combinatorial Chemistry</a></td>
<td>Rutjes, F., Fokin, V. V. (eds.)</td>
<td>978-3-527-32085-1</td>
</tr>
<tr>
<td><a href="#">Enzyme Catalysis in Organic Synthesis</a></td>
<td>Drauz, K., Gröger, H., May, O. (eds.)</td>
<td>978-3-527-32547-4</td>
</tr>
<tr>
<td><a href="#">Third, completely revised and enlarged edition</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="#">3 Volumes</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="#">Modern Biocatalysis</a></td>
<td>Fessner, W.-D., Anthonsen, T.</td>
<td>978-3-527-32071-4</td>
</tr>
<tr>
<td><a href="#">Stereoselective and Environmentally Friendly Reactions</a></td>
<td>Lutz, S., Bornscheuer, U. T. (eds.)</td>
<td></td>
</tr>
<tr>
<td><a href="#">Protein Engineering Handbook</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="#">2 Volume Set</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="#">Peptides: Chemistry and Biology</a></td>
<td>Sewald, N., Jakubke, H.-D.</td>
<td>978-3-527-31867-4</td>
</tr>
<tr>
<td><a href="#">Peptides from A to Z</a></td>
<td>Jakubke, H.-D., Sewald, N.</td>
<td></td>
</tr>
<tr>
<td><a href="#">A Concise Encyclopedia</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="#">Classics in Total Synthesis III</a></td>
<td>Nicolaou, K. C., Chen, J. S.</td>
<td>978-3-527-32958-8 (Hardcover)</td>
</tr>
<tr>
<td><a href="#">New Targets, Strategies, Methods</a></td>
<td></td>
<td>978-3-527-32957-1 (Softcover)</td>
</tr>
</tbody>
</table>
Edited by
Andrew B. Hughes

Amino Acids, Peptides and Proteins in Organic Chemistry

Volume 4 - Protection Reactions, Medicinal Chemistry, Combinatorial Synthesis

WILEY-VCH Verlag GmbH & Co. KGaA
Contents

List of Contributors  XVII

1 Protection Reactions  1
Vommima V. Sureshbabu and Narasimhamurthy Narendra
1.1 General Considerations  1
1.2 α-Amino Protection (Nε Protection)  4
1.2.1 Non-Urethanes  4
1.2.1.1 Acyl Type  4
1.2.1.1.1 Monoacyl Groups  5
1.2.1.2 Groups Cleavable via Lactam Formation  6
1.2.1.3 Diacyl Groups  7
1.2.1.2 Phosphine-Type Groups  10
1.2.1.3 Sulfonyl-Type Groups  10
1.2.1.4 Alkyl-Type Groups  11
1.2.1.4.1 Triphenylmethyl (Trityl or Trt) Group  11
1.2.1.4.2 Benzhydryl Groups  12
1.2.1.4.3 N,N-Bis-Benzyl Protection  12
1.2.1.4.4 Vinyl Groups  12
1.2.1.5 Sulfanyl-Type Groups  13
1.2.2 Urethanes (Carbamates or Alkyloxycarbonyl Groups)  14
1.2.2.1 Formation of the Urethane Bond  16
1.2.2.2 Urethanes Derived from Primary Alcohols  16
1.2.2.2.1 Benzylxycarbonyl (Cbz or Z) Group  16
1.2.2.2.2 Urethanes Cleaved by β-Elimination  19
1.2.2.2.3 Urethanes Cleaved via Michael-Type Addition  24
1.2.2.2.4 Allyloxycarbonyl (Aloc) Group  25
1.2.2.3 Urethane Groups Derived from Secondary Alcohols  25
1.2.2.4 Urethanes Derived from Tertiary Alcohols  25
1.2.2.4.1 tert-Butyloxycarbonyl (Boc) Group  25
1.2.2.4.2 Boc Analogs  28
1.2.2.5 Other Aspects of Urethane Protectors  29

Amino Acids, Peptides and Proteins in Organic Chemistry.
Vol.4 – Protection Reactions, Medicinal Chemistry, Combinatorial Synthesis. Edited by Andrew B. Hughes
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 978-3-527-32103-2
1.2.2.5.1 Formation of Dipeptide Impurities during the Introduction of Urethanes and Protocols to Overcome It 29
1.2.2.5.2 Introduction of Urethanes via Transprotection 30
1.2.2.5.3 Protection of the Nitrogen of α-Amino Acid N-Carboxy Anhydrides (NCAs) 31
1.2.2.5.4 N\textsuperscript{a}-N\textsuperscript{a}-bis-Protected Amino Acids 32
1.2.3 Other N\textsuperscript{a}-Protecting Groups 32
1.2.3.1 α-Azido Acids as α-Amino Acid Precursors 33
1.2.3.2 One-Pot N\textsuperscript{a} Protection and C\textsuperscript{a} Activation 33
1.2.3.3 Effect of N\textsuperscript{a}-Protecting Groups in the Synthesis of NMAs 33
1.3 Carboxy Protection 34
1.3.1 Methyl and Ethyl Esters 35
1.3.1.1 Substituted Methyl and Ethyl Esters 36
1.3.2 Benzyl Ester 36
1.3.2.1 Cleavage 36
1.3.3 Substituted Benzyl Esters 38
1.3.4 tert-Butyl Ester 38
1.3.5 Other Acid-Labile Esters 39
1.3.6 Temporary α-Carboxy Protection 39
1.3.7 α-Carboxy Protectors as Precursors to Useful Amino Acid Derivatives: Formation of Acid Hydrazides 41
1.4 Side-Chain Protection 41
1.4.1 ω-Amino Group of Diamino Acids 41
1.4.2 Guanidino Group of Arg 43
1.4.2.1 Protection Through Protonation 43
1.4.2.2 Nitration 44
1.4.2.3 Arg Precursors 45
1.4.3 Imidazole Group of His 45
1.4.4 Indole Group of Trp 48
1.4.5 ω-Amino Group of Asn and Gln 49
1.4.6 β-Thiol Group of Cys 50
1.4.6.1 Common Side-Reactions with S-Protected Cys Derivatives 51
1.4.6.1.1 Racemization 51
1.4.6.1.2 β-Elimination 51
1.4.6.1.3 Oxidation 51
1.4.6.2 Synthesis of Peptides Using Cystine as “Self-Protected” Cys 51
1.4.7 Thioether Group of Met 53
1.4.8 Hydroxy Group of Ser, Thr, and the Phenolic Group of Tyr 54
1.4.9 ω-Carboxy Group of Asp and Glu 55
1.4.9.1 Aspartimide Formation 55
1.5 Photocleavable Protections 57
1.6 Conclusions 58
1.7 Experimental Procedures 59
1.7.1 Protection Reactions 59
1.7.1.1 General Procedure for the Preparation of Tfa-Arg-OH 59
1.7.1.2 General Procedure for the Preparation of $N^\alpha$-Phthaloyl Amino Acids using $N$-(Ethoxycarbonyl)phthalimide  59
1.7.1.3 General Procedure for the Preparation of $N^\alpha$-Trt-Amino Acids  59
1.7.1.4 General Procedure for the Preparation of $N^\alpha$-Ns-Amino Acids  60
1.7.1.5 General Procedure for the Preparation of $N^\alpha$-Z-Amino Acids  61
1.7.1.5.1 Method A: Using Z-Cl  61
1.7.1.5.2 Method B: Using Z-OSu  62
1.7.1.6 General Procedures for the Preparation of $N^\alpha$-Fmoc-Amino Acids  62
1.7.1.6.1 Method A: Using Fmoc-OSu  62
1.7.1.6.2 Method B: Using Fmoc-Cl and $N,O$-bis-TMS-Amino Acids  62
1.7.1.6.3 Method C: Using Fmoc-Cl in the Presence of Zinc Dust  63
1.7.1.6.4 Method D: Using Fmoc-$N_3$  63
1.7.1.7 General Procedure for the Preparation of $N^\alpha$-Nsc-Amino Acids  64
1.7.1.8 General Procedure for the Preparation of $N^\alpha$-Bsmoc-Amino Acids  64
1.7.1.9 General Procedure for the Preparation of $N^\alpha$-Aloc-Amino Acids  65
1.7.1.10 General Procedures for the Preparation of $N^\alpha$-Boc-Amino Acids  65
1.7.1.10.1 Method A: Using (Boc)$_2$O  65
1.7.1.10.2 Method B: Using Boc-ON  65
1.7.1.10.3 Method C: Using Boc-$N_3$  66
1.7.1.11 General Procedure for the Preparation of $N,N^\alpha$-di-Boc-Amino Acids  66
1.7.1.12 General Procedure for the Preparation of $N^\alpha$-Bpoc-Amino Acids  67
1.7.1.13 General Procedures for the Preparation of Amino Acid Methyl Esters  68
1.7.1.13.1 Preparation of Amino Acid Methyl Ester Hydrochloride Salts  68
1.7.1.13.2 Isolation of Amino Acid Methyl Esters: Deprotonation of the Hydrochloride Salt Using Zinc Dust  69
1.7.1.13.3 Glutamic Acid $\alpha$-Methyl, $\gamma$-tert-Butyl Diester Using Diazomethane  69
1.7.1.13.4 Z-Glu-OMe via Methanolysis of Cyclic Anhydride  69
1.7.1.14 General Procedure for the Preparation of Amino Acid Ethyl Esters  69
1.7.1.15 General Procedure for the Preparation of Amino Acid Benzyl Ester p-Toluenesulfonate Salts  70
1.7.1.15.1 Preparation of Amino Acid Benzyl Ester p-Toluenesulfonate Salts Under Microwave Irradiation  70
1.7.1.16 General Procedure for the Preparation of $\text{tert}$-Butyl Esters of $N^\alpha$-Unprotected Amino Acids Using Isobutene  71
1.7.1.16.1 Preparation of Z-Phe-OtBu by the Silver Salt Method  71
1.7.1.17 General Procedure for Concomitant Protection and Activation of Amino Acids Using Pentfluorophenyl Carbonate  80
1.7.2 Deprotection Reactions 81
1.7.2.1 Removal of the Phth Group by Hydrazinolysis 81
1.7.2.2 Removal of the Nps Group 81
1.7.2.3 Removal the Z-group 82
1.7.2.3.1 Protocol A: Employing CH 82
1.7.2.3.2 Protocol B: Employing Silylhydride 82
1.7.2.3.3 Protocol C: Through CTH using 1,4-Cyclohexadieneas Hydrogen Donor 83
1.7.2.4 Cleavage of the Fmoc Group 83
1.7.2.4.1 Method A: Using TAEA [67] 83
1.7.2.4.2 Method B: Using DEA: Simultaneous Removal of the Fmoc Group and 9-Fluorenymethyl Ester 83
1.7.2.5 Cleavage of the Boc Group 84
1.7.2.5.1 Protocol A: Removal of the Boc group with TFA in the Presence of Scavengers 84
1.7.2.5.2 Protocol B: Cleavage of Boc Group with TMS/Phenol 84
1.7.2.6 Transprotection of Nα-Protecting Groups: Fmoc-Met-OH to Boc-Met-OH 84
1.7.2.7 Selective Methyl Ester Hydrolysis in the Presence of the Nα-Fmoc Group 84
1.7.2.8 Cleavage of tert-Butyl Ester Using BF₃·Et₂O 84
1.7.2.9 Selective Cleavage of Phenacyl Ester in the Presence of the Nα-Nosyl Group 85
1.7.2.10 Removal of the Trt Group (Iodolysis) 85
1.7.2.11 Deprotection of the Pbf Group from Z-Arg(Pbf)-OH 85
1.7.2.12 Removal of the Phenoc Group through Photolysis 85
1.7.2.13 Conversion of the DCHA Salt of Nα-Protected Amino Acids into Free Acids 85

References 86

Part One Amino Acid-Based Peptidomimetics 99

2 Huisgen Cycloaddition in Peptidomimetic Chemistry 101

Daniel Sejer Pedersen and Andrew David Abell

2.1 Introduction 101
2.2 Huisgen [2 + 3] Cycloaddition Between Azides and Acetylenes 102
2.3 Mechanistic Consideration for the Cu-Huisgen and Ru-Huisgen Cycloadditions 103
2.4 Building Blocks for the Synthesis of Triazole-Modified Peptidomimetics 106
2.5 Cyclic Triazole Peptidomimetics 109
2.6 Acyclic Triazole Peptidomimetics 113
2.7 Useful Experimental Procedures 121
5 Medicinal Chemistry of Alicyclic β-Amino Acids 175
Nils Griebenow
5.1 Introduction 175
5.2 Five-Membered Alicyclic β-Amino Acids 175
5.3 Six-Membered Alicyclic β-Amino Acids 183
References 186

6 Medicinal Chemistry of α-Hydroxy-β-Amino Acids 189
Zyta Ziora, Mariusz Skwarczynski, and Yoshiaki Kiso
6.1 Introduction 189
6.2 α-Hydroxy-β-Amino Acids 189
6.2.1 α-Hydroxy-β-Amino Acids Occurring in Natural Products 189
6.2.2 Synthesis of α-Hydroxy-β-Amino Acids 191
6.2.2.1 Isoserine 191
6.2.2.2 Isothreonine 193
6.2.2.3 Phenylisoserine 197
6.2.2.4 Norstatines 197
6.2.2.5 3-Amino-2-Hydroxydecanoic Acid and its Analogs 204
6.2.2.6 Synthetic Demands 205
6.3 Antibacterial Agents 205
6.4 Inhibitors of Aminopeptidases 207
6.5 Aspartyl Proteases Inhibitors 211
6.5.1 Renin Inhibitors 212
6.5.2 HIV-1 Protease Inhibitors 216
6.5.3 HTLV-I Inhibitors 220
6.5.4 Plasmepsin II Inhibitors 222
6.5.5 BACE-1 Inhibitors 224
6.6 Paclitaxel and its Derivatives 228
References 234

7 Peptide Drugs 247
Chiara Falciani, Alessandro Pini, and Luisa Bracci
7.1 Lights and Shades of Peptide and Protein Drugs 247
7.2 Peptide Drugs Available on the Market 249
7.2.1 Natriuretic Peptide (Nesiritide) 249
7.2.2 Oxytocin 249
7.2.3 Vasopressin 250
7.2.4 Desmopressin 251
7.2.5 Blood Coagulation Inhibitors 251
7.2.5.1 Bivalirudin 251
7.2.5.2 Integrilin (Eptifibatide) 251
7.2.6 Gonadotropin-Releasing Hormone Agonists and Antagonists 251
7.2.6.1 Gonadorelin 251
7.2.6.2 Lupron (Leuprolide) 252
7.2.6.3 Cetrorelix 253
7.2.6.4 Degarelix 253
7.2.7 Antihyperglycemics 254
7.2.7.1 Symlin (Pramlintide) 254
7.2.7.2 Exendin-4 254
7.2.7.3 Liraglutide 255
7.2.8 Icatibant 255
7.2.9 Sermorelin 256
7.2.10 Calcitonin 256
7.2.11 Parathyroid Hormone 256
7.2.12 Cyclosporine 257
7.2.13 Fuzeon 257
7.3 Approved Peptides in Oncology 258
7.3.1 Bortezomib 259
7.3.2 Actinomycin D 259
7.3.3 Marimastat 260
7.3.4 Octreotide 260
7.3.5 Vapreotide 261
7.3.6 Octreoscan 262
7.4 Antimicrobial peptides 263
7.4.1 Polymyxin 265
7.4.2 Daptomycin 266
7.4.3 Gramicidin S 267
7.5 Perspectives 267
7.5.1 Branched Peptides as Tumor-Targeting Agents 268
7.5.2 Branched Peptides as Antimicrobials 270
7.6 References 271

8 Oral Bioavailability of Peptide and Peptidomimetic Drugs 277
Arik Dahan, Yasuhiro Tsume, Jing Sun, Jonathan M. Miller, and Gordon L. Amidon
8.1 Introduction 277
8.2 Fundamental Considerations of Intestinal Absorption 277
8.3 Barriers Limiting Oral Peptide/Peptidomimetic Drug Bioavailability 279
8.4 Strategies to Improve Oral Bioavailability of Peptide-Based Drugs 280
8.4.1 Chemical Modifications 280
8.4.1.1 Prodrug Approach 280
8.4.1.2 Structural Modifications 281
9 Asymmetric Synthesis of β-Lactams via the Staudinger Reaction

Monika I. Konaklieva and Balbina J. Plotkin

9.1 Introduction 293
9.2 Staudinger Reaction 293
9.3 Influence of the Geometry of the Imine on Stereoselectivity in the Reaction 294
9.4 Influence of the Polarity of the Solvent on Stereoselectivity of the Reaction 296
9.5 Influence of the Isomerization of the Imine Prior to its Nucleophilic Attack onto the Ketene Stereoselectivity in the Reaction 296
9.6 Influence of the Order of Addition of the Reactants to the Reaction 297
9.7 Influence of Chiral Substituents on the Stereoselectivity of the Reaction 298
9.8 Asymmetric Induction from the Imine Component 298
9.9 Asymmetric Induction from the Ketene Component 305
9.10 Double Asymmetric Cycloinduction 308
9.11 Influence of Catalysts on the Stereoselectivity of the Reaction 309
9.11.1 General Procedure for β-Lactams 106 with Proton Sponge 312
9.11.2 General Procedure for the Tandem Nucleophile/Lewis Acid-Promoted Synthesis of β-Lactams 110 312
9.11.3 General Procedure for Catalytic Asymmetric Synthesis of Trans-β-Lactams 113 314
9.11.4 Example for Kinugasa Reaction with Cu (II) Catalyst 316
9.11.4.1 General Procedure for Catalytic Asymmetric Synthesis of β-Lactams 122 316
9.12 Conclusions 316
References 317

10 Advances in N- and O-Glycopeptide Synthesis – A Tool to Study Glycosylation and Develop New Therapeutics

Ulrika Westerlind and Horst Kunz

10.1 Introduction 321
10.2 Synthesis of O-Glycopeptides 324
10.2.1 Synthesis of Mucin-Type Glycopeptides 325
10.2.1.1 Synthesis of Tumor-Associated Glycopeptides and Glycopeptide Vaccines 325
10.2.1.1.1 Synthesis of Tn, T, Sialyl-Th, and Sialyl-T Glycosylated Amino Acid Building Blocks 325
10.2.1.1.2 Synthesis of Tn, T, Sialyl-Th, and Sialyl-T Glycopeptides and Vaccines 329
10.2.1.2 Synthesis of Glycopeptide Recognition Domain of P-Selectin Glycoprotein Ligand-1 331
10.2.1.2.1 Synthesis of a Core 2 sLex Amino Acid Building Block Including a sLe^x Mimic 332
10.2.1.2.2 Synthesis of Unsulfated and Sulfated Core 2 sLe^x and Core 2 sLe^x Mimic PSGL-1 Glycopeptides 334
10.2.1.2.3 Chemoenzymatic Synthesis of Unsulfated and Sulfated sLe^x PSGL-1 Glycopeptide 336
10.2.2 Synthesis of Other Types of O-Glycopeptides 339
10.2.2.1 Synthesis of Fmoc-GlcNAc-Ser/Thr Amino Acids 340
10.2.2.2 Synthesis of Estrogen Receptor Peptides for Conformational Analysis 340
10.3 Synthesis of N-Glycopeptides 342
10.3.1 Synthesis of RNase C Glycoprotein 343
10.3.2 Synthesis of Erythropoietin N-Glycopeptide Fragment 1–28 346
10.3.2.1 Synthesis of Biantennary Dodecasaccharide 346
10.3.2.2 Synthesis of N-Glycopeptide Fragment 1–28 348
10.3.3 Chemoenzymatic Synthesis of a HIV GP120 V3 Domain N-Glycopeptide 350
10.3.3.1 Synthesis of the Oxazoline Tetrasaccharide Donor 350
10.3.3.2 Synthesis of Fmoc-GlcNAc-Asn Amino Acid Building Block 351
10.3.3.3 Synthesis of V3 Cyclic GlcNAc Peptide and Endo A Coupling with Man3GlcNAc Oxazoline Donor 352
References 353

11 Recent Developments in Neoglycopeptide Synthesis 359
Margaret A. Brimble, Nicole Miller, and Geoffrey M. Williams
11.1 Introduction 359
11.2 Neoglycoside and Neoglycopeptide Synthesis 361
11.2.1 S-Glycosides 361
11.2.2 N-Glycosides 362
11.2.3 O-Glycosides 364
11.2.4 C-Glycosides 365
11.2.5 C=N Linkage 365
11.3 Protein Side-Chain Modifications 366
11.3.1 Modifications of Cysteine Side-Chains 366
11.3.2 Modifications of Lysine Side-Chains 369
11.3.3 Other Side-Chain Modifications 370
11.4 Cu(I)-Catalyzed Azide–Alkyne “Click” Cycloaddition 372
11.4.1 General Aspects of Cu(I)-Catalyzed Azide–Alkyne cycloaddition 372
11.4.2 Neoglycoside and Neoglycopeptide Synthesis via CuAAC 373
11.4.3 CuAAC and Neoglycoproteins 376
11.5 Cross-Metathesis 378
11.6 Application of Neoglycopeptides as Synthetic Vaccines 380
11.7 Enzymatic, Molecular, and Cell Biological Techniques 384
11.7.1.1 Enzymatic Glycoprotein Synthesis 385
11.7.2 Molecular and Cell Biological Techniques 385
References 386

Part Three Amino Acids in Combinatorial Synthesis 393

12 Combinatorial/Library Peptide Synthesis 395
Michal Lebl
12.1 Introduction 395
12.2 High-Throughput Synthesis of Peptides 396
12.2.1 Parallel Peptide Synthesis 396
12.2.2 Directed Sorting 400
12.3 Synthesis of Peptide Arrays 402
12.4 Peptide Libraries 406
12.4.1 Synthesis of Peptide Mixtures 406
12.4.2 Synthesis of Peptides on a Mixture of Particles 409
12.4.2.1 Determination of the Structure of a Peptide on an Individual Bead 416
12.4.3 Solution-Based Screening of OBOC Libraries 418
12.5 Future of Peptide Libraries 421
12.6 Synthetic Protocols 421
12.6.1 Pin Synthesis 421
12.6.2 SPOT Synthesis 422
12.6.3 Synthesis in Tea-Bags 422
12.6.4 Synthesis on Cotton 423
12.6.4.1 Modification of the Cotton Carrier 423
12.6.5 Split-and-Mix Synthesis of OBOC Noncleavable Libraries 424
12.6.6 Preparation of Dual-Layer Beads 425
12.6.7 Preparation of Library of Libraries 426
12.6.8 Preparation of OBOC Libraries for Testing in Solution 426
12.6.8.1 Synthesis of Multicleavable Linker 426
12.6.8.2 Synthesis of the Library 428
12.6.8.3 Quality Control of the Doubly Releasable Library 428
12.6.8.4 Two-Stage Release Assay in 96-Well Microassay Plates 429
12.6.9 Synthesis of the Positional Scanning Library 430
12.6.10 Synthesis of the Dual Defined Iterative Hexapeptide Library 430
12.6.11 Acylation Monitoring by Bromophenol Blue 431
References 432

13 Phage-Displayed Combinatorial Peptides 451
Renhua Huang, Kritika Pershad, Malgorzata Kokoszka, and Brian K. Kay
13.1 Introduction 451
13.1.1 Types of Phage Vectors 452
13.1.2 Generation of Combinatorial Peptide Libraries 455
13.1.3 Identifying Peptide Ligands to Protein Targets 458
13.1.4 Mapping Protein–Protein Interactions 461
13.1.5 Identifying Peptide Ligands Binding to Cell Surfaces 463
13.1.6 Mapping Protease Specificity 464
13.1.7 Identifying Peptide Ligands to the Surfaces of Inert Materials 464
13.2 Conclusions 465
References 466

14 Designing New Proteins 473
Michael I. Sadowski and James T. MacDonald
14.1 Introduction 473
14.1.1 Why Design New Proteins? 473
14.1.2 How New is “New?” 474
14.2 Protein Design Methods 475
14.2.1 Computational Design 476
14.2.1.1 Computational Enzyme Design 477
14.2.1.2 Results of Computational Design Experiments 478
14.2.2 Directed Evolution Methods 480
14.2.2.1 Randomization Strategies 480
14.2.2.2 Expression Systems and Assays 481
14.2.3 Design of Protein Interfaces 482
14.3 Protocol for Protein Design 484
14.4 Conclusions 486
References 487

15 Amino Acid-Based Dendrimers 491
Zhengshuang Shi, Chunhui Zhou, Zhigang Liu, Filbert Totsingan, and Neville R. Kallenbach
15.1 Introduction 491
15.2 Peptide Dendrimer Synthesis: Divergent and Convergent Approaches 491
15.2.1 Synthesis of the First Peptide Dendrimers: Polylsine Dendrimers 493
15.2.2 Glutamic/Aspartic Acid, Proline, and Arginine Dendrimers 494
15.2.3 Synthesis of MAPs 497
15.2.4 Synthesis of Peptide Dendrimers Grafted on PAMAM and other Peptide Dendrimers 500
15.3 Applications of Peptide Dendrimers 502
15.3.1 Initial Efforts on MAPs 502
15.3.2 Peptide Dendrimers as Antimicrobial Agents 502
15.3.3 Peptide Dendrimers as Protein/Enzyme Mimics 504
15.3.4 Peptide Dendrimers as Ion Sensors and MRI Contrast Agents 505
15.3.5 Peptide Dendrimers as DNA/RNA Delivery Vectors 507
15.3.6 Other Application of Peptide Dendrimers 512
15.4 Conclusions 513
References 514

Index 519
List of Contributors

Andrew David Abell
University of Adelaide
School of Chemistry and Physics
North Terrace
Adelaide, South Australia 5005
Australia

Gordon L. Amidon
University of Michigan
College of Pharmacy
Department of Pharmaceutical Sciences
428 Church Street
Ann Arbor, MI 48109
USA

Luisa Bracci
University of Siena
Department of Biotechnology
Laboratory of Molecular Biotechnology
Via Fiorentina 1
53100 Siena
Italy

Margaret A. Brimble
University of Auckland
Department of Chemistry
23 Symonds Street
1043 Auckland
New Zealand

Lennart Bunch
University of Copenhagen
Faculty of Pharmaceutical Sciences
Department of Medicinal Chemistry
Universitetsparken 2
2100 Copenhagen
Denmark

Arik Dahan
Ben-Gurion University of the Negev
School of Pharmacy
Faculty of Health Sciences
Department of Clinical Pharmacology
Beer-Sheva 84105
Israel

David P. Fairlie
University of Queensland
Institute for Molecular Bioscience
Division of Chemistry and Structural Biology
306 Carmody Rd
Brisbane, Queensland 4072
Australia

Chiara Falciani
University of Siena
Department of Biotechnology
Laboratory of Molecular Biotechnology
Via Fiorentina 1
53100 Siena
Italy
List of Contributors

Nils Griebenow
Bayer Schering Pharma
Medicinal Chemistry
Aprather Weg 18a
42096 Wuppertal
Germany

Renhua Huang
University of Illinois at Chicago
Department of Biological Sciences
845 W. Taylor Street
Chicago, IL 60607-7060
USA

Neville R. Kallenbach
New York University
Department of Chemistry
100 Washington Square East
New York, NY 10003-5180
USA

Monika I. Konaklieva
American University
Department of Chemistry
4400 Massachusetts Avenue, NW
Washington, DC 20016
USA

Povl Krogsgaard-Larsen
University of Copenhagen
Faculty of Pharmaceutical Sciences
Department of Medicinal Chemistry
Universitetsparken 2
2100 Copenhagen
Denmark

Horst Kunz
Johannes Gutenberg-Universität
Institut für Organische Chemie
Duesbergweg 10–14
55128 Mainz
Germany

Michal Lebl
Institute of Organic Chemistry and Biochemistry AS CR
Department of Peptide Chemistry
166 10 Praha 6
Czech Republic

Zhigang Liu
New York University
Department of Chemistry
100 Washington Square East
New York, NY 10003-5180
USA

Wendy A. Loughlin
Griffith University
Science, Engineering, Environment and Technology Group
Nathan Campus N55 Kessels Rd
Brisbane, Queensland 4111
Australia

Yoshiaki Kiso
Kyoto Pharmaceutical University
Center for Frontier Research in Medicinal Science
Department of Medicinal Chemistry
21st Century COE Program
Yamashina-ku
607-8412 Kyoto
Japan

Malgorzata Kokoszka
University of Illinois at Chicago
Department of Biological Sciences
845 W. Taylor Street
Chicago, IL 60607-7060
USA
List of Contributors

James T. MacDonald  
Medical Research Council  
National Institute for Medical Research  
The Ridgeway, Mill Hill  
London NW7 1AA  
UK

Jonathan M. Miller  
University of Michigan  
College of Pharmacy  
Department of Pharmaceutical Sciences  
428 Church Street  
Ann Arbor, MI 48109  
USA

Nicole Miller  
University of Auckland  
Department of Chemistry  
23 Symonds Street  
1043 Auckland  
New Zealand

Narasimhamurthy Narendra  
Bangalore University  
Department of Studies in Chemistry  
Central College Campus  
Dr. B.R. Ambedkar Veedhi  
Bangalore 560001  
Karnataka  
India

Daniel Sejer Pedersen  
University of Copenhagen  
Faculty of Pharmaceutical Sciences  
Department of Medicinal Chemistry  
Universitetsparken 2  
2100 Copenhagen  
Denmark

Kritika Pershad  
University of Illinois at Chicago  
Department of Biological Sciences  
845 W. Taylor Street  
Chicago, IL 60607-7060  
USA

Alessandro Pini  
University of Siena  
Department of Biotechnology  
Laboratory of Molecular Biotechnology  
Via Fiorentina 1  
53100 Siena  
Italy

Balbina J. Plotkin  
Midwestern University  
Department of Microbiology and Immunology  
555 31st Street  
Downers Grove, IL 60515  
USA

Michael I. Sadowski  
Medical Research Council  
National Institute for Medical Research  
The Ridgeway, Mill Hill  
London NW7 1AA  
UK

Zhengshuang Shi  
New York University  
Department of Chemistry  
100 Washington Square East  
New York, NY 10003-5180  
USA

Mariusz Skwarczynski  
The University of Queensland  
School of Chemistry and Molecular Biosciences  
St Lucia, Brisbane, Queensland 4072  
Australia

Jing Sun  
University of Michigan  
College of Pharmacy  
Department of Pharmaceutical Sciences  
428 Church Street  
Ann Arbor, MI 48109  
USA
List of Contributors

**Vommena V. Sureshbabu**
Bangalore University  
Department of Studies in Chemistry  
Central College Campus  
Dr. B.R. Ambedkar Veedhi  
Bangalore 560001  
Karnataka  
India

**Filbert Totsingan**
New York University  
Department of Chemistry  
100 Washington Square East  
New York, NY 10003-5180  
USA

**Yasuhiro Tsume**
University of Michigan  
College of Pharmacy  
Department of Pharmaceutical Sciences  
428 Church Street  
Ann Arbor, MI 48109  
USA

**Geoffrey M. Williams**
University of Auckland  
Department of Chemistry  
23 Symonds Street  
1043 Auckland  
New Zealand

**Chunhui Zhou**
New York University  
Department of Chemistry  
100 Washington Square East  
New York, NY 10003-5180  
USA

**Zyta Ziora**
The University of Queensland  
Centre for Integrated Preclinical Drug Development-Pharmaceutics  
St Lucia, Brisbane, Queensland 4072  
Australia

**Ulrika Westerlind**
Gesellschaft zur Förderung der Analytischen Wissenschaften e.V.  
ISAS - Leibniz Institute of Analytical Sciences  
Otto-Hahn-Strasse 6b  
44227 Dortmund  
Germany
1 Protection Reactions

Vommima V. Sureshbabu and Narasimhamurthy Narendra

1.1 General Considerations

Peptides, polypeptides, and proteins are the universal constituents of the biosphere. They are responsible for the structural and functional integrity of cells. They form the chemical basis of cellular functions that are based on highly specific molecular recognition and binding, and are involved as key participants in cellular processes. A peptide or a protein is a copolymer of α-amino acids that are covalently linked through a secondary amide bond (called a peptide bond). They differ from one another by the number and sequence of the constituent amino acids. Generally, a molecule comprised of few amino acids is called an oligopeptide and that with many amino acids is a polypeptide (molecular weight below 10 000). Proteins contain a large number of amino acids. Due to the vitality of their role for the function as well as survival of cells, peptides and proteins are continuously synthesized. Biosynthesis of proteins is genetically controlled. A protein molecule is synthesized by stepwise linking of unprotected amino acids through the cellular machinery comprised of enzymes and nucleic acids, and functioning based on precise molecular interactions and thermodynamic control. Thousands of proteins/peptides are assembled through the combination of only 20 amino acids (referred to as coded or proteinogenic amino acids). Post-translational modifications (after assembly on ribosomes) such as attachment of nonpeptide fragments, functionalization of amino acid side-chains and the peptide backbone, and cyclization reactions confer further structural diversity on peptides.

The production of peptides via isolation from biological sources or recombinant DNA technology is associated with certain limitations per se. A minor variation in the sequence of a therapeutically active peptide isolated from a microbial or animal source relative to that of the human homolog is sufficient to cause hypersensitivity in some recipients. Further, the active drug component is often not a native peptide but a synthetic analog, which may have been reduced in size or may contain additional functional groups and non-native linkages. The development of a drug from a lead peptide involves the synthesis (both by conventional and combinatorial methods) and screening of a large number of analogs. Consequently, the major proportion of the
demand for peptides is still met by chemical synthesis. Chemical synthesis is also crucial for synthesizing peptides with unnatural amino acids as well as peptide mimics, which by virtue of the presence of non-native linkages are inaccessible through ribosomal synthesis.

Synthetic peptides have to be chemically as well as optically homogenous to be able to exhibit the expected biological activity. This is typically addressed by using reactions that furnish high yields, give no or minimum side-products, and do not cause stereomutation. In addition, the peptide of interest has to be scrupulously purified after synthesis to achieve the expected level of homogeneity. The general approach to synthesize a peptide is stepwise linking of amino acids until the desired sequence is reached. However, the actual synthesis is not as simple as the approach appears to be due to the multifunctional nature of the amino acids. Typically, a proteinogenic amino acid (except Gly) contains a chiral carbon atom to which is attached the amino (α-amino), carboxy, and alkyl group (referred to as the side-chain). Gly lacks the alkyl substitution at the α-carbon atom. Also, the side-chains of many of the amino acids are functionalized.

A straightforward approach to prepare a dipeptide A–B would be to couple the carboxy-activated amino acid A with another amino acid B. However, this reaction will yield not only the expected dipeptide A–B, but also an A–A (through self-acylation) due to the competing amino group of A. The so-formed dipeptides can further react with A since they bear free amino groups and form oligopeptides A–A–B, A–A–A, or A–A–A–A, and the reaction proceeds uncontrollably to generate a mixture of self-condensation products (homopolymers) and oligopeptides of the type A_nB. The process becomes even more complicated when reactive functional groups are present in the side-chains of the reacting amino acid(s). The uncontrolled reactivity of multiple groups leads to the formation of a complex mixture from which it becomes a Sisyphean task to isolate the desired product, which would have been formed, mostly, in low yield. The solution to carry out peptide synthesis in a chemoselective way is to mask the reactivity of the groups on amino acids that will not be the components of the peptide bond prior to peptide coupling step. This is done by converting the intervening functional group into an unreactive (or less reactive) form by attaching to it a new segment, referred to as a protecting group (or protection or protective function). The chemical reactions used for this purpose are known as protection reactions. The protecting groups are solely of synthetic interest and are removed whenever the functional group has to be regenerated. In other words, the protection is reversible. In the light of the concept of protection, the steps involved in the synthesis of the above dipeptide A–B are depicted in Figure 1.1.

Protections are employed for α-amino, carboxy, and side-chain functional groups (Figure 1.2). Since peptide synthesis is a multistep and repetitive process, the longevity of different protecting groups on the peptide under synthesis varies. In the present and widely followed approach of assembling peptides, wherein the peptide chain extension is from the carboxy- to amino-terminus (C → N direction), the α-amino protection is removed after each peptide coupling step to obtain a free amino group for subsequent acylation and, hence, this protection is temporary. The carboxy and side-chain protections are generally retained until the entire sequence
is assembled, and are removed simultaneously in a single step at the end of the synthesis. Hence, they can be regarded as semipermanent groups. The transient α-amino protection should be removed using reagents/conditions that do not affect the stability of semipermanent groups and, importantly, the newly assembled peptide bond(s). Consequently, it should be orthogonal to semipermanent groups with respect to its susceptibility to a particular cleavage reaction. Sometimes it may be required to remove only the carboxy protection or a particular side-chain protection in order to obtain a $N^\alpha$-protected peptide acid or to regenerate a side-chain functional group (for site-selective peptide modification). In such cases, the α-amino and semipermanent groups have to be orthogonal to one another.

In practice, the orthogonality among protecting groups is achieved by either differential reactivities or different rates of reaction of protective units towards a particular cleavage reagent. The compulsion for the requirement of semipermanent groups can be lifted especially with respect to the protection of side-chain functionalities if there is no possibility of an undesired reaction from the unprotected group during coupling or deprotection of the α-amino group. Hence, the degree of protection can widely vary (from maximum to minimum) depending upon the synthetic design and the choice of chemistry.

An ideal protecting group should be quantitatively introduced and removed (desirably using mild reagents/conditions), should leave no residue nor form a byproduct that is difficult to separate from the product, should not be prematurely deblocked or modified during synthesis, and should not cause side-reactions including stereomutation. In addition, it should not influence the reactivity of the adjacent groups or, if it does, it should be in predictable ways.

**Figure 1.1** Illustration of synthesis of a dipeptide using α-amino and carboxy protections.

**Figure 1.2** Side-chain functional groups of amino acids that entail protection.
In this chapter, various α-amino, carboxy, and side-chain protecting groups are presented. The general features of each type of protecting groups, methods of introduction and removal, and improved analogs are discussed. Typical and widely used preparative methods are mentioned under each category of protecting groups. The reader may refer to many earlier works for accounts on the development of protecting groups and for detailed discussions on different aspects of protecting group chemistry in peptide synthesis [1].

1.2

α-Amino Protection (Nα Protection)

The α-amino group is protected to reduce its nucleophilicity. In addition to the general properties of a protecting group, an ideal α-amino protection is expected to possess more properties unique to itself. Deblocking of the Nα protection should take place with a high degree of selectivity so that there will be no progressive loss of the semipermanent groups with repetitive deblocking steps as the peptide chain is elongated. The Nα protection should not sterically or electronically disfavor the reactions at the carboxy group by virtue of its proximity. It should not be involved or promote side-reactions, including those that lead to stereomutation. Further, it should form stable and crystallizable amino acid derivatives. Indeed, due to such stringent requirements for a α-amino protecting group, the success in the development of a good Nα protection has always been critical to progress in the development of efficient coupling methods and, in turn, to the overall growth of the field of peptide synthesis.

The α-amino protections are of different types and they can be categorized using different approaches. However, based on the criteria of the magnitude of the present utility of each type, the groups can be classified into non-urethane- and urethane-type N protections. Presently, the latter are the extensively used Nα-protecting groups for both solution and solid-phase peptide synthesis (SPPS) due to reasons that will be discussed later. The extent of the utility of the non-urethane-type amino protectors in peptide synthesis is currently comparatively lesser. Only a few groups of this category have been demonstrated to be efficient as Nα-protectors for general applications. Nonetheless, they are useful as protecting groups for side-chain functions as well as for the protection of the α-amino group for the synthesis of peptide mimics and unnatural amino acids. Their importance in peptidomimetic synthesis owes much to the vast diversity in chemistry required for accomplishing a wide range of backbone modifications of peptides leading to novel nonpeptidic molecules.

1.2.1

Non-Urethanes

1.2.1.1 Acyl Type

Reaction of amino acids with alkyl or aryl carboxylic acid derivatives yields N-acyl amines or amides. Acyl groups were the first generation of Nα-protecting groups used for peptide synthesis. The necessity for the protection of the α-amino group for
successful peptide synthesis was identified as early as 1900s by the two distinguished chemists of the time, Emil Fischer and Theodor Curtius, who mostly employed formyl (For), acetyl (Ac), and benzoyl (Bz) groups for this purpose. However, it was soon realized that the selective removal of these protections from peptides was not successful. The acyl groups present two synthetic difficulties in general – difficulty in the removal of the group without destroying the meticulously assembled peptide bonds and a high degree of racemization of Nα-acyl-protected amino acid derivatives. The only mode of deprotection of an acyl-protected amine is the fission of the acyl-nitrogen (\(-\text{CO}–\text{NH}\)-) bond. However, since the peptide bonds (secondary amides) are chemically similar to the amide bond (of the protective function), they are often simultaneously cleaved. Although selective removal of the Nα-acyl group has been attempted through special methods such as the enzymatic and CNBr-mediated cleavage of N-terminal Z-Arg and Met peptides, respectively, these protocols have not found widespread application. However, if the Nα-acyl group contains an electron-withdrawing substitution (e.g., CF₃CO-, trifluoroacetyl (Tfa) group), then the amide carbonyl of the protective function becomes more susceptible to nucleophilic substitution relative to the peptide carbonyl and thus the amino group can be selectively deprotected under acceptable conditions. Selectivity can also be achieved by using groups that can be modified (postcoupling) into units, which can be eliminated through processes such as lactam formation. Barring these examples, simple acyl groups do not find established applications as α-amino protections for conventional peptide synthesis. Nonetheless, the For protection can be attributed with a unique application. The Nα-formyl group of protected amino acid esters/amides and peptide esters 1 can be readily dehydrated into the isocyanate group and the resulting α-isocyanate esters/amides 2 can be used as key components to synthesize peptides and peptide libraries through multicomponent reactions (MCRs). MCRs have been shown to be particularly useful to assemble peptides linked by sterically hindered amino acids such as α,α-dialkylamino acids. For instance, an extremely difficult sequence 4 with three successive α,α-diphenylglycine (Dph) units has been assembled through a modified Ugi reaction of isonitrile 3 with Z-Dph-OH and diphenylmethanimine (Figure 1.3) [2]. Mild and racemization free conversion of Nα-For-protected amino acid and peptide derivatives into isonitriles can be carried out by the treatment with triphosgene in dichloromethane (DCM) at \(-75\) to \(-30\,^\circ\text{C}\) (Figure 1.3) or Burgess reagent [3].

1.2.1.1.1 **Monoacyl Groups**

**Trifluoroacetyl (Tfa) Group** Tfa is of special interest as a monoacyl-type protecting group. Due to the negative inductive effect of the \(-\text{CF}_3\) substitution, the trifluoroacetamides readily undergo hydrolysis in mild alkaline conditions to which peptide bonds and most carboxy esters are largely stable, not withstanding methyl and ethyl esters (which are susceptible to saponification). Optically pure Nα-Tfa-amino acids are prepared by treating amino acids with trifluoroacetic anhydride (TFAA) in anhydrous trifluoroacetic acid (TFA) solvent at \(-10\) to \(+10\,^\circ\text{C}\) [4]. The method can also be successfully used to obtain Nα-Tfa-Lys/Orn from Lys/Orn. The acidity of the
medium protonates the more basic ω-amino group of Lys/Orn into the ammonium form, which do not undergo acylation. However, the strong acidic condition is disadvantageous in the case of preparation of Tfa-Ser-OH and Tfa-Thr-OH as these hydroxy amino acids are dehydrated into unsaturated amino acids. Trifluoroacetylation can also be carried out using ethyl thioesters and phenyl/alkyl esters of TFA such as ethyl trifluoroacetate [4] or reagents such as 1-(trifluoroacetyl)imidazole. The Nα-Tfa group is cleaved by the action of 0.2 N NaOH [5] or Ba(OH)₂ or by dilute NH₃ solution. Piperidine [6] and NaBH₄ in EtOH can also be employed. The group is resistant to acids except for Tfa-Ser/Thr derivatives in which it is cleaved by mild acidic reagents. However, strong acidic conditions such as boiling methanolic HCl can cleave the group.

1.2.1.1.2 Groups Cleavable via Lactam Formation 2-(4,5-Dimethyl-2-nitrophenoxyl)-2-methylpropionyl group 5a and its phenyldiazenyl analog 5b are introduced by the reaction of the corresponding acid chlorides with amino acids. Cleavage is accomplished in two steps (Figure 1.4). The first step is the reduction of the nitro group into an amino group by catalytic hydrogenation or catalytic transfer hydrogenation (CTH). Step 2 is the cyclization of the resulting amino compound 6 into a lactam 7 at neutral pH with concomitant elimination of the protected amine [7]. A similar process also cleaves 5b [8]. Nevertheless, incomplete reduction and cyclization steps have been the major concerns for a broad application of these groups in spite of selective and acceptable cleavage conditions.

Racemization The high degree of racemization of Nα-acyl-protected amino acids has been attributed to the facile formation of optically labile azlactone intermediates

![Figure 1.3](image-url) Synthesis of isocyanato peptides from N-For-protected peptide esters and the Ugi four-component reaction of α-isocyanato esters.

![Figure 1.4](image-url) Cleavage of Nα protection via lactam formation.
Activated N\(^\alpha\)-acyl amino acids readily undergo base-catalyzed ring closure to azlactones (2,4-disubstituted oxazol-5(4\(H\))-ones). Enolization of the latter to oxazol-5-ol 9 in the presence of a base results in the loss of chirality at the \(\alpha\)-carbon atom. Azlactones can acylate amines, but the resulting product will be a mixture of epimeric peptides (10 and 11, Figure 1.5). In the case of N-methyl-\(\alpha\)-amino acids (NMAs), the oxazolium intermediate can be formed even in the absence of base, due to the electron-releasing effect of the N-alkyl substitution. Hence, N\(^\alpha\)-acyl, N\(^\alpha\)-alkylated amino acid derivatives are extremely sensitive to racemization during coupling. Base-catalyzed enolization of the activated amino acid derivatives with the abstraction of the \(\alpha\)-proton also contributes to racemization.

Racemization can also take place during the introduction of N\(^\alpha\)-acyl protection because of the \textit{in situ} activation of the carboxy group by acid anhydrides and acid chlorides (used as reagents for acylation of \(\alpha\)-amino group) followed by cyclization to azlactones. For instance, the N\(^\alpha\)-Tfa-aminos prepared by the treatment of amino acids with an excess of TFAA in the absence of TFA have been found to be contaminated with the D-isomer. This is due to the activation of Tfa-amino acids by TFAA to unsymmetrical or symmetrical anhydrides, which rearrange with racemization to the corresponding Tfa-azlactones.

1.2.1.1.3 Diacyl Groups Reaction of amino acids with 1,2-dicarboxylic acid derivatives yields imides that are stable to acids and also to hydrogenolysis, thus making the diacyl-type protection suitable for usage in diverse synthetic conditions. These groups are cleaved by nucleophilic substitution by hydrazine or thiols. The aromatic 1,2-dicarboxylic acid, phthalic acid, is employed for N\(^\alpha\) protection, whereas the alkyl counterpart N-maleoyl group has been replaced by the dithiasuccinoyl (Dts) group.

**Phthaloyl (Phth) Group** N\(^\alpha\)-Protected Phth-aminos 12 are prepared under mild and racemization-free conditions by using phthaloylating reagents (Figures 1.6 and 1.7) such as N-(ethoxycarbonyl)phthalimide 13, monoethyl phthalate 14 [9], and
3-chloro-3-(dimethoxyphosphoryl)isobenzofuran-1(3H)-one 15 [10]. N-Phthaloylation by these reagents has almost completely replaced the original and harsh route of fusing amino acids with phthalic anhydride, which invariably caused racemization. An improvement in the method was achieved by using solvents such as benzene, dioxane, and so on, but could not overcome the racemization problem completely.

The N'-Phth group is normally removed by means of hydrazinolysis by treatment with hydrazine hydrate in refluxing MeOH or EtOH [11]. Alternatively, a two-step procedure, which involves a reductive ring opening, followed by an acid-catalyzed lactonization of the resulting hydroxy compound (17) with concomitant fission of acyl-nitrogen bond, has also been developed (Figure 1.8) [12]. Interestingly, Phth protection cannot be removed by treatment with alkali. The alkali opens the five membered ring to a monoacyl amide of phthalic acid 18 (O-carboxybenzoyl amide) which is stable to hydrazine and to bases, thus representing an irreversible protection. Hence, saponification cannot be used as a method to cleave esters of N'-Phth-protected peptide acids. On the other hand, treatment with SOCl₂ or methanolic HCl converts 18 back to phthalimide. In fact, this cyclization has been used as the basis for the development of a mild protocol for preparation of phthalimides. Tetrachlorophthaloyl group is an improved analog of Phth and can be removed under mild conditions by treatment with 15% hydrazine in N,N'-dimethylformamide (DMF) for 1 h at room temperature [13].

**Groups Removed by Reductive Cleavage** Dithiasuccinoyl (Dts) imides are stable to acids and to photolysis, and are cleaved by reductive thiolysis. N'-Dts-amino acids 19 are prepared through a multistep route, which involves the reaction of the tert-butyl esters of amino acids with alkylthiocarbonate or trithiodicarbonate to form

![Figure 1.7 Phthaloylating reagents.](image1)

![Figure 1.8 Cleavage of the N'-Phth group.](image2)